Antitumor effects of celecoxib in COX-2 expressing and non-expressing canine melanoma cell lines

Kyoung Won Seo, Ye rin Coh, Robert B Rebhun, Jin ok Ahn, Sei Myung Han, Hee woo Lee, Hwa Young Youn

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Cyclooxygenase-2 (COX-2) is a potential target for chemoprevention and cancer therapy. Celecoxib, a selective COX-2 inhibitor, inhibits cell growth of various types of human cancer including malignant melanoma. In dogs, oral malignant melanoma represents the most common oral tumor and is often a fatal disease. Therefore, there is a desperate need to develop additional therapeutic strategies. The purpose of this study was to investigate the anticancer effects of celecoxib on canine malignant melanoma cell lines that express varying levels of COX-2. Celecoxib induced a significant anti-proliferative effect in both LMeC and CMeC-1 cells. In the CMeC cells, treatment of 50 μM celecoxib caused an increase in cells in the G0/G1 and a decreased proportion of cells in G-2 phase. In the LMeC cells, 50 μM of celecoxib led to an increase in the percentage of cells in the sub-G1 phase and a significant activation of caspase-3 when compared to CMeC-1 cells. In conclusion, these results demonstrate that celecoxib exhibits antitumor effects on canine melanoma LMeC and CMeC-1 cells by induction of G1-S cell cycle arrest and apoptosis. Our data suggest that celecoxib might be effective as a chemotherapeutic agent against canine malignant melanoma.

Original languageEnglish (US)
Pages (from-to)482-486
Number of pages5
JournalResearch in Veterinary Science
Volume96
Issue number3
DOIs
StatePublished - 2014

Fingerprint

Celecoxib
prostaglandin synthase
Cyclooxygenase 2
melanoma
Canidae
Melanoma
cell lines
Cell Line
dogs
cells
neoplasms
mouth
G1 Phase Cell Cycle Checkpoints
Neoplasms
therapeutics
Gastrin-Secreting Cells
chemoprevention
Cyclooxygenase 2 Inhibitors
Chemoprevention
G1 Phase

Keywords

  • Antitumor effects
  • Canine melanoma
  • Celecoxib
  • COX-2 inhibitors

ASJC Scopus subject areas

  • veterinary(all)
  • Medicine(all)

Cite this

Antitumor effects of celecoxib in COX-2 expressing and non-expressing canine melanoma cell lines. / Seo, Kyoung Won; Coh, Ye rin; Rebhun, Robert B; Ahn, Jin ok; Han, Sei Myung; Lee, Hee woo; Youn, Hwa Young.

In: Research in Veterinary Science, Vol. 96, No. 3, 2014, p. 482-486.

Research output: Contribution to journalArticle

Seo, Kyoung Won ; Coh, Ye rin ; Rebhun, Robert B ; Ahn, Jin ok ; Han, Sei Myung ; Lee, Hee woo ; Youn, Hwa Young. / Antitumor effects of celecoxib in COX-2 expressing and non-expressing canine melanoma cell lines. In: Research in Veterinary Science. 2014 ; Vol. 96, No. 3. pp. 482-486.
@article{8a8519b51ecc41e4bf61c6fe5b1194fa,
title = "Antitumor effects of celecoxib in COX-2 expressing and non-expressing canine melanoma cell lines",
abstract = "Cyclooxygenase-2 (COX-2) is a potential target for chemoprevention and cancer therapy. Celecoxib, a selective COX-2 inhibitor, inhibits cell growth of various types of human cancer including malignant melanoma. In dogs, oral malignant melanoma represents the most common oral tumor and is often a fatal disease. Therefore, there is a desperate need to develop additional therapeutic strategies. The purpose of this study was to investigate the anticancer effects of celecoxib on canine malignant melanoma cell lines that express varying levels of COX-2. Celecoxib induced a significant anti-proliferative effect in both LMeC and CMeC-1 cells. In the CMeC cells, treatment of 50 μM celecoxib caused an increase in cells in the G0/G1 and a decreased proportion of cells in G-2 phase. In the LMeC cells, 50 μM of celecoxib led to an increase in the percentage of cells in the sub-G1 phase and a significant activation of caspase-3 when compared to CMeC-1 cells. In conclusion, these results demonstrate that celecoxib exhibits antitumor effects on canine melanoma LMeC and CMeC-1 cells by induction of G1-S cell cycle arrest and apoptosis. Our data suggest that celecoxib might be effective as a chemotherapeutic agent against canine malignant melanoma.",
keywords = "Antitumor effects, Canine melanoma, Celecoxib, COX-2 inhibitors",
author = "Seo, {Kyoung Won} and Coh, {Ye rin} and Rebhun, {Robert B} and Ahn, {Jin ok} and Han, {Sei Myung} and Lee, {Hee woo} and Youn, {Hwa Young}",
year = "2014",
doi = "10.1016/j.rvsc.2014.03.003",
language = "English (US)",
volume = "96",
pages = "482--486",
journal = "Research in Veterinary Science",
issn = "0034-5288",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Antitumor effects of celecoxib in COX-2 expressing and non-expressing canine melanoma cell lines

AU - Seo, Kyoung Won

AU - Coh, Ye rin

AU - Rebhun, Robert B

AU - Ahn, Jin ok

AU - Han, Sei Myung

AU - Lee, Hee woo

AU - Youn, Hwa Young

PY - 2014

Y1 - 2014

N2 - Cyclooxygenase-2 (COX-2) is a potential target for chemoprevention and cancer therapy. Celecoxib, a selective COX-2 inhibitor, inhibits cell growth of various types of human cancer including malignant melanoma. In dogs, oral malignant melanoma represents the most common oral tumor and is often a fatal disease. Therefore, there is a desperate need to develop additional therapeutic strategies. The purpose of this study was to investigate the anticancer effects of celecoxib on canine malignant melanoma cell lines that express varying levels of COX-2. Celecoxib induced a significant anti-proliferative effect in both LMeC and CMeC-1 cells. In the CMeC cells, treatment of 50 μM celecoxib caused an increase in cells in the G0/G1 and a decreased proportion of cells in G-2 phase. In the LMeC cells, 50 μM of celecoxib led to an increase in the percentage of cells in the sub-G1 phase and a significant activation of caspase-3 when compared to CMeC-1 cells. In conclusion, these results demonstrate that celecoxib exhibits antitumor effects on canine melanoma LMeC and CMeC-1 cells by induction of G1-S cell cycle arrest and apoptosis. Our data suggest that celecoxib might be effective as a chemotherapeutic agent against canine malignant melanoma.

AB - Cyclooxygenase-2 (COX-2) is a potential target for chemoprevention and cancer therapy. Celecoxib, a selective COX-2 inhibitor, inhibits cell growth of various types of human cancer including malignant melanoma. In dogs, oral malignant melanoma represents the most common oral tumor and is often a fatal disease. Therefore, there is a desperate need to develop additional therapeutic strategies. The purpose of this study was to investigate the anticancer effects of celecoxib on canine malignant melanoma cell lines that express varying levels of COX-2. Celecoxib induced a significant anti-proliferative effect in both LMeC and CMeC-1 cells. In the CMeC cells, treatment of 50 μM celecoxib caused an increase in cells in the G0/G1 and a decreased proportion of cells in G-2 phase. In the LMeC cells, 50 μM of celecoxib led to an increase in the percentage of cells in the sub-G1 phase and a significant activation of caspase-3 when compared to CMeC-1 cells. In conclusion, these results demonstrate that celecoxib exhibits antitumor effects on canine melanoma LMeC and CMeC-1 cells by induction of G1-S cell cycle arrest and apoptosis. Our data suggest that celecoxib might be effective as a chemotherapeutic agent against canine malignant melanoma.

KW - Antitumor effects

KW - Canine melanoma

KW - Celecoxib

KW - COX-2 inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84899949575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899949575&partnerID=8YFLogxK

U2 - 10.1016/j.rvsc.2014.03.003

DO - 10.1016/j.rvsc.2014.03.003

M3 - Article

VL - 96

SP - 482

EP - 486

JO - Research in Veterinary Science

JF - Research in Veterinary Science

SN - 0034-5288

IS - 3

ER -